Myeloablative regimens: multivariate analysis of outcomes
| Outcome . | No. of events/evaluable . | HR (95% CI) . | P . |
|---|---|---|---|
| Grades 2 to 4 acute GVHD* | |||
| Haplo | 296/801 | 1.00 | |
| MUD | 32/95 | 0.92 (0.65-1.32) | .65 |
| Grades 3 and 4 acute GVHD* | |||
| Haplo | 87/798 | 1.00 | |
| MUD | 4/95 | 0.37 (0.14-1.00) | .050 |
| Chronic GVHD† | |||
| Haplo | 249/811 | 1.00 | |
| MUD, PTCy/CNI/MMF | 24/97 | 0.66 (0.43-1.01) | .053 |
| Relapse‡ | |||
| Haplo | 154/824 | 1.00 | |
| MUD | 19/97 | 1.03 (0.64-1.66) | .91 |
| Nonrelapse mortality§ | |||
| Haplo | 122/824 | 1.00 | |
| MUD | 14/97 | 0.77 (0.44-1.34) | .35 |
| Disease-free survival║ | |||
| Haplo | 276/824 | 1.00 | |
| MUD | 33/97 | 0.89 (0.62-1.38) | .53 |
| Overall survival¶ | |||
| Haplo | 202/824 | 1.00 | |
| MUD | 21/97 | 0.70 (0.44-1.09) | .12 |
| Outcome . | No. of events/evaluable . | HR (95% CI) . | P . |
|---|---|---|---|
| Grades 2 to 4 acute GVHD* | |||
| Haplo | 296/801 | 1.00 | |
| MUD | 32/95 | 0.92 (0.65-1.32) | .65 |
| Grades 3 and 4 acute GVHD* | |||
| Haplo | 87/798 | 1.00 | |
| MUD | 4/95 | 0.37 (0.14-1.00) | .050 |
| Chronic GVHD† | |||
| Haplo | 249/811 | 1.00 | |
| MUD, PTCy/CNI/MMF | 24/97 | 0.66 (0.43-1.01) | .053 |
| Relapse‡ | |||
| Haplo | 154/824 | 1.00 | |
| MUD | 19/97 | 1.03 (0.64-1.66) | .91 |
| Nonrelapse mortality§ | |||
| Haplo | 122/824 | 1.00 | |
| MUD | 14/97 | 0.77 (0.44-1.34) | .35 |
| Disease-free survival║ | |||
| Haplo | 276/824 | 1.00 | |
| MUD | 33/97 | 0.89 (0.62-1.38) | .53 |
| Overall survival¶ | |||
| Haplo | 202/824 | 1.00 | |
| MUD | 21/97 | 0.70 (0.44-1.09) | .12 |
Model unadjusted, no significant factors.
Model adjusted for graft type (peripheral blood: HR, 2.06; 95% CI, 1.48-2.87; P < .0001).
Model adjusted for disease risk index (high-risk: HR, 1.80; 95% CI, 1.28-2.53; P = .0007) and conditioning regimen (non-TBI: HR, 1.59; 95% CI, 1.17-2.16; P = .003).
Model adjusted for age (>55 y: HR, 2.76; 95% CI, 1.95-3.92; P < .0001), hematopoietic comorbidity index (≥3: HR, 1.53; 95% CI, 1.08-2.15, P = .015), and conditioning regimen (non-TBI: HR, 1.46; 95% CI, 1.01-2.09; P = .04).
Model adjusted for age (>55 y: HR, 1.62; 95% CI, 1.28-2.05; P < .0001), hematopoietic comorbidity index (≥3: HR, 1.37; 95% CI, 1.09-1.72; P = .006), disease risk index (high-risk: HR, 1.66; 95% CI, 1.29-2.14; P = .0001), and conditioning regimen (non-TBI: HR, 1.55; 95% CI, 1.22-1.97; P = .003).
Model adjusted for age (>55 y: HR, 2.03; 95% CI, 1.54-2.67; P < .0001), hematopoietic comorbidity index (≥3: HR, 1.40; 95% CI, 1.07-1.82; P = .02), disease risk index (high-risk: HR, 1.60; 95% CI, 1.19-2.16; P = .002), and conditioning regimen (non-TBI: HR, 1.65; 95% CI, 1.24-2.19; P = .0006).